MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds.
Recursion Pharmaceuticals Inc. (RXRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 34,815,502 | $184,174,004 | +8% | 1.84% |
| 2. | MIC Capital Partners Mubadala Investment | 9,644,032 | $51,016,935 | -1% | 10.39% |
| 3. | Citadel Investment Group Ken Griffin | 2,655,711 | $14,048,711 | -4% | 0% |
| 4. | Laurion Capital Management Benjamin A. Smith | 1,547,407 | $8,185,783 | -38% | 0.21% |
| 5. | 1,359,885 | $7,193,792 | +4% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 66,822 | $522,354.26 | 12,985,927 | 2023-03-02 | Filing | |
| $7.94 | 48,867 | $388,082.17 | 12,919,105 | 2023-03-01 | Filing | |
| $7.97 | 815 | $6,495.55 | 12,870,238 | 2023-02-28 | Filing | |
| $7.69 | 52,500 | $403,725.00 | 12,869,423 | 2023-02-27 | Filing | |
| $7.64 | 109,118 | $833,552.40 | 12,816,923 | 2023-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.04 | 138,574 | $836,986.96 | 1,117,450 | 2025-03-27 | Filing | |
| $6.37 | 20,000 | $127,400.00 | 1,256,024 | 2025-03-06 | Filing | |
| $6.58 | 20,000 | $131,600.00 | 1,256,024 | 2025-03-05 | Filing | |
| $8.12 | 20,000 | $162,400.00 | 1,273,156 | 2025-02-06 | Filing | |
| $7.68 | 20,000 | $153,600.00 | 1,273,156 | 2025-02-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,020 | $10,222 | 0% | |
| 2. | 2,000 | $10,120 | 0% | |
| 3. | 17 | $86 | 0% | |
| 4. | 0 | $0 | 0% |
News See All
11 Best AI Stocks to Buy According to Hedge Funds
Keith Lerner, co-chief investment officer at Truist Wealth, joined CNBC's "Closing Bell" on June 27 to discuss how the bull market's dominant theme is AI.
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock.
10 AI Stocks That Will Skyrocket
In a bold move that highlights just how transformative artificial intelligence is becoming, Amazon CEO Andy Jassy recently warned employees that the company’s growing reliance on AI will likely lead...
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI
We recently published a list of 15 Stocks That Stole The Show Last Week.
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Did Jim Cramer Nail or Miss These 11 Stock Predictions?
During the most recent episode of Mad Money, which aired on Tuesday the 27th of May, Jim Cramer opened with a passionate defense of the artificial intelligence boom, warning viewers not to dismiss the...
10 Most Popular AI Stocks to Avoid Now
Over the last two years, artificial intelligence has been the central theme driving equities to record highs amid expectations that its technological innovations will change how the world works.
Billionaire Hedge Funds
